India Pharma Outlook Team | Friday, 08 August 2025
Eli Lilly's weight loss drug Mounjaro has rocketed through the Indian pharma market, quickly surging to ?100 crore in the first four months of launch, according to PharmaTrac data.
Mounjaro sales were already just shy of ?50 crore for July alone—more than 2x the previous month. If the momentum continues, Mounjaro sales are on track to exceed ?500 crore by March, which would make Mounjaro one of the fastest-growing prescription brands in India by total sales revenue.
Launched in late March, Mounjaro (tirzepatide) has already established significant patient adoption, with nearly 1.6 lakh units sold—vastly outpacing Wegovy, which launched in June and sold just 5,000 units in two months for ?10 crore.
Also Read: How Pharma Contract Manufacturing Can Win Big in Weight-Loss Drugs
“Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,” said Sheetal Sapale, vice president, commercial, at PharmaTrac.
Experts say the success of Mounjaro is attributed to its weight loss efficacy (20-22%) as compared to Wegovy (16-18%), as well as, the price point being in the ?14,000-?17,500 range compared to Wegovy's ?17,345-?26,050.
“As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,” Sapale said.
Mounjaro's growing adoption and physician preference in prescribing midget a swift capturing of market share. However, we may see price pressures in this segment if and when generic semaglutide—Wegovy's ingredient—enters the market. Industry watchers will be monitoring how Mounjaro sales continue to impact the landscape for anti-obesity drugs in India.
